Clinical Trial Update: Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating topical hydrocortisone 0.335% (Softacort) for efficacy in chronic dry eye disease with ocular surface inflammation completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Softacort (hydrocortisone 0.335%)

Snippet

Sponsor: Medical University of Vienna | Conditions: Dry Eye | Phase 4 | Status: COMPLETED